<div class="article">
	<h3>Business Brief -- Wellcome PLC:
   British Drug Firm's Profit
   Gained 28% in Six Months</h3>
	<div class="article-info">
		<ul>
			<li>Author: null</li>
			<li>Date: 05/04/90</li>
		</ul>
	</div>
	<p class="article-leader">Wellcome PLC said pretax profit rose 28% for the six
months ended March 3 helped by improved profits in all of the
company's major operations.
   The British pharmaceuticals group said pretax profit rose
to #164.1 million ($269.5 million) from #128.2 million, at
the top end of market expectations of #155 million to #165
million.</p>
	<div class="article-body"><p>But Wellcome dropped 21 pence to 655 pence on London's
Stock Exchange, as analysts said they were expecting a more
bullish report on the company's Retrovir drug, which is used
to fight acquired immune deficiency syndrome.</p>
<p>Profit after tax and minority interests, or profit
attributable to shareholders, was #97.8 million, up from
#76.2 million. Per-share earnings increased to 11.5 pence
from nine pence.</p>
<p>Wellcome declared an interim per-share dividend to 1.5
pence, up 15% from 1.3 pence.</p>
<p>Sales rose 9% to #733.4 million from #672.7 million.
Excluding #92.9 million from its discontinued Coopers Animal
Health subsidiary, the group's latest sales figure improved
28%.</p>
<p></p></div>
</div>
